<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881244</url>
  </required_header>
  <id_info>
    <org_study_id>AS1411-C-101</org_study_id>
    <nct_id>NCT00881244</nct_id>
  </id_info>
  <brief_title>Study of AS1411 in Advanced Solid Tumours</brief_title>
  <official_title>Phase I Open Label Study of AS1411 in Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antisoma Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antisoma Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I open label study of AS1411 in advanced solid tumours. Objectives include
      determining the MTD and DLT of AS1411, to determine the PK profile of AS1411 and to obtain
      preliminary evidence of clinical and biological responses to AS1411 therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of AS1411</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic (PK) distribution and profile of AS1411</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain preliminary evidence of clinical and biological responses to AS1411</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS1411</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS1411</intervention_name>
    <description>I.v. 4-7 days, 1-40 mg/kg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced solid tumours that were refractory to conventional/standard
             treatment

          -  Age &gt;/ 18 years

          -  ECOG performance status &lt;/ 2 (Karnofsky &gt;/60%

          -  Life expectancy &gt;/ 8 weeks

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Radiotherapy or chemotherapy in the 4 weeks before study entry (6 weeks for
             nitrosourea or mitomycin C

          -  Lack of recovery from adverse events (AEs) caused by agents administered before study
             entry; current use of other investigational agent(s)

          -  Uncontrolled brain metastases including a need for corticosteroid therapy

          -  Pregnancy

          -  Uncontrolled intercurrent illness

          -  Psychiatric illness/social situations that could limit compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chris Smyth, VP Clinical Operations</name_title>
    <organization>Antisoma</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

